Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.79 | N/A | -38.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.79 | N/A | -38.44% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions affecting performance. They highlighted their commitment to navigating these challenges.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Kodiak Sciences reported a larger-than-expected loss per share, which reflects ongoing challenges in their operations. Despite the EPS miss, the stock rose by 2.31%, likely due to investors' optimism about the company's long-term potential and management's commitment to addressing current issues. The lack of revenue data and guidance may leave some investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Feb 28, 2022